Product Description
WGI-0301 is a lipid nanoparticle preparation of Archexin® for the treatment of advanced solid tumors. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05267899)
Mechanisms of Action: miRNA-21 Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Zhejiang Haichang Biotech
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hepatocellular Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06309485 |
WGI0301-P2G-01 | P2 |
Not yet recruiting |
Hepatocellular Carcinoma |
2026-08-01 |
30% |
2024-03-14 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|